share_log

Tempus AI | 10-Q: Q3 2024 Earnings Report

Tempus AI | 10-Q: Q3 2024 Earnings Report

Tempus AI | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/04 16:10

Moomoo AI 已提取核心訊息

Tempus AI, Inc. reported robust financial results for Q3 2024, with total revenue increasing 33% year-over-year to $180.9 million. Genomics revenue grew 20% to $116.4 million, while Data and services revenue surged 64% to $64.5 million. The company performed approximately 69,000 oncology NGS tests during the quarter, up from 55,700 in Q3 2023.The company continued to invest heavily in research and development, with expenses increasing to $58 million compared to $47.4 million in Q3 2023. Operating expenses rose to $234.5 million from $180.8 million last year, primarily due to $21 million in stock-based compensation and increased personnel costs. Net loss widened to $75.8 million from $53.4 million in Q3 2023.Tempus strengthened its strategic position by announcing the acquisition of Ambry Genetics for $375 million in cash plus 4.8 million shares of Class A common stock. The company also expanded internationally through its joint venture with SoftBank in Japan, contributing $95.2 million to form SB Tempus. The company maintained a strong balance sheet with $388.9 million in cash and cash equivalents as of September 30, 2024.
Tempus AI, Inc. reported robust financial results for Q3 2024, with total revenue increasing 33% year-over-year to $180.9 million. Genomics revenue grew 20% to $116.4 million, while Data and services revenue surged 64% to $64.5 million. The company performed approximately 69,000 oncology NGS tests during the quarter, up from 55,700 in Q3 2023.The company continued to invest heavily in research and development, with expenses increasing to $58 million compared to $47.4 million in Q3 2023. Operating expenses rose to $234.5 million from $180.8 million last year, primarily due to $21 million in stock-based compensation and increased personnel costs. Net loss widened to $75.8 million from $53.4 million in Q3 2023.Tempus strengthened its strategic position by announcing the acquisition of Ambry Genetics for $375 million in cash plus 4.8 million shares of Class A common stock. The company also expanded internationally through its joint venture with SoftBank in Japan, contributing $95.2 million to form SB Tempus. The company maintained a strong balance sheet with $388.9 million in cash and cash equivalents as of September 30, 2024.
Tempus AI公司公佈了2024年第三季度強勁的財務業績，總營業收入同比增長33%，達到18090萬美元。基因組學營業收入增長20%，達到11640萬美元，而數據和服務營業收入激增64%，達到6450萬美元。該公司在該季度進行了大約69,000例腫瘤NGS測試，較2023年第三季度的55,700例有所增加。公司繼續大力投資於研發，費用增加至5800萬美元，而2023年第三季度爲4740萬美元。營業費用從去年的18080萬美元上升至23450萬美元，主要由於2100萬美元的基於股票的補償和增加的人事成本。淨虧損從2023年第三季度的5340萬美元擴大至7580萬美元。Tempus通過宣佈以現...展開全部
Tempus AI公司公佈了2024年第三季度強勁的財務業績，總營業收入同比增長33%，達到18090萬美元。基因組學營業收入增長20%，達到11640萬美元，而數據和服務營業收入激增64%，達到6450萬美元。該公司在該季度進行了大約69,000例腫瘤NGS測試，較2023年第三季度的55,700例有所增加。公司繼續大力投資於研發，費用增加至5800萬美元，而2023年第三季度爲4740萬美元。營業費用從去年的18080萬美元上升至23450萬美元，主要由於2100萬美元的基於股票的補償和增加的人事成本。淨虧損從2023年第三季度的5340萬美元擴大至7580萬美元。Tempus通過宣佈以現金37500萬美元和480萬股A類普通股收購Ambry Genetics，進一步增強了其戰略地位。該公司還通過與軟銀在日本的合資企業擴大了國際業務，爲Sb Tempus貢獻了9520萬美元。截止到2024年9月30日，公司保持了強勁的資產負債表，現金及現金等價物爲38890萬美元。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Performant Healthcare
    PHLT
    -- 3.000
    SHL Telemedicine
    SHLT
    -- 1.950
    Simulations Plus
    SLP
    -- 24.290
    Mangoceuticals
    MGRX
    -- 2.380
    Forian
    FORA
    -- 2.000
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點